Jacobson Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Jacobson Pharma has a total shareholder equity of HK$2.5B and total debt of HK$652.4M, which brings its debt-to-equity ratio to 26.6%. Its total assets and total liabilities are HK$3.6B and HK$1.2B respectively. Jacobson Pharma's EBIT is HK$341.2M making its interest coverage ratio 14.2. It has cash and short-term investments of HK$515.9M.
Key information
26.6%
Debt to equity ratio
HK$652.40m
Debt
| Interest coverage ratio | 14.2x |
| Cash | HK$515.90m |
| Equity | HK$2.46b |
| Total liabilities | HK$1.15b |
| Total assets | HK$3.61b |
Recent financial health updates
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Recent updates
There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Financial Position Analysis
Short Term Liabilities: 2633's short term assets (HK$1.1B) exceed its short term liabilities (HK$516.5M).
Long Term Liabilities: 2633's short term assets (HK$1.1B) exceed its long term liabilities (HK$634.5M).
Debt to Equity History and Analysis
Debt Level: 2633's net debt to equity ratio (5.6%) is considered satisfactory.
Reducing Debt: 2633's debt to equity ratio has reduced from 54% to 26.6% over the past 5 years.
Debt Coverage: 2633's debt is well covered by operating cash flow (74.2%).
Interest Coverage: 2633's interest payments on its debt are well covered by EBIT (14.2x coverage).